Immix Biopharma
IMMX
12 hedge funds and large institutions have $730K invested in Immix Biopharma in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 9 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.28% less ownership
Funds ownership: 3.16% → 2.88% (-0.28%)
28% less capital invested
Capital invested by funds: $1.01M → $730K (-$281K)
33% less funds holding
Funds holding: 18 → 12 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UB
UMB Bank
Kansas City,
Missouri
|
+$219K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.2K |
| 3 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$23.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.88K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$154K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$76.9K |
| 3 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$58K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$43.9K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$36K |
IMMX Hedge Fund Activity: Q1 2023 in Review
12 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2023, worth a combined $730K — down 28% from $1.01M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IMMX and 3 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was UMB Bank, opening a new position worth an estimated $219K. The largest seller was Murchinson, exiting entirely with an estimated $154K sold.
- 12 institutional investors held Immix Biopharma (IMMX) as of Q1 2023, down from 18 in Q4 2022.
- Funds reported $730K of Immix Biopharma stock for Q1 2023, down 28% quarter-over-quarter.
- 3 funds opened new Immix Biopharma positions in Q1 2023 and 9 closed out, a net change of -6 holders.
- The largest Immix Biopharma buyer in Q1 2023 was UMB Bank, an estimated $219K added.
- The largest Immix Biopharma seller in Q1 2023 was Murchinson, an estimated $154K sold.
Based on aggregated 13F filings for Q1 2023.